Drug intelligence / Profile preview

besonprodil

Development stage: Preclinical
Lead developer: Pfizer
Modality: Small Molecules

Overview

Besonprodil (CI-1041) is a highly selective small molecule antagonist of the NR2B subunit-containing N-methyl-D-aspartate (NMDA) receptors. It was developed as an investigational compound possessing anticonvulsant activity, with particular selectivity for blocking NMDA receptors that include the NR2B subunit. In preclinical models, CI-1041 modulates excitatory synaptic NMDA receptor activity, potentially relevant to neurological and anticonvulsant indications[1][3].

Targets

GRIN2B (N-methyl-D-aspartate Receptor Subunit Combination: NR1a/NR2B)

Beyond the preview

Go deeper on besonprodil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on besonprodil.

Explore the full profile